Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Chiesi grants Curosurf license, invests in Cornerstone

Executive Summary

Italy's Chiesi Farmaceutici SPA has granted spec pharma Cornerstone Therapeutics an exclusive US license to sell its porcine-derived lung surfactant Curosurf (poractant alfa) for the next ten years (renewable thereafter automatically in one-year increments). Cornerstone also obtained the first right of offer on any drugs or technologies--most likely in the respiratory field, including Phase I synthetic surfactant Nymusa for sleep apnea--which Chiesi plans to launch in the US.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Marketing (Licensing)

Related Companies